Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | CMO & Head of Development | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 19,794 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Exercise / conversion · Acquired 10,833 · Balance 19,794 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. |
| Class A Common StockSEC Table I · non-derivative | Direct | 8,961 |
Reported balance
After 2026-06-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-30 · Sale · Disposed 10,833 · Balance 8,961 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3: Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2035-04-27 | Direct | 238,334 |
Reported balance
After 2026-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-30 · Exercise / conversion · Disposed 10,833 · Balance 238,334 F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3: Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
F4: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 10,833 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001628280-26-046654 · wk-form4_1782947093.xml · derivative · entry 3 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,334 Underlying: Class A Common Stock · 10,833 shares Expires 2035-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 10,833 | $16.02 | $173,590.16 |
DisclosureSEC source: 0001628280-26-046654 · wk-form4_1782947093.xml · nonDerivative · entry 2 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,961 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 23:04 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 10,833 | $4.50 | $48,748.50 |
DisclosureSEC source: 0001628280-26-046654 · wk-form4_1782947093.xml · nonDerivative · entry 1 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:28 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 3,611 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001437749-26-006421 · rdgdoc.xml · derivative · entry 3 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 249,167 Underlying: Class A Common Stock · 3,611 shares Expires 2035-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · derivative.exercise_date: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:28 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 3,611 | $15.02 | $54,220.25 |
DisclosureSEC source: 0001437749-26-006421 · rdgdoc.xml · nonDerivative · entry 2 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:28 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 3,611 | $4.50 | $16,249.50 |
DisclosureSEC source: 0001437749-26-006421 · rdgdoc.xml · nonDerivative · entry 1 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| January 30, 2026 Filed Jan 30, 2026 21:52 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001437749-26-002575 · rdgdoc.xml · derivative · entry 5 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,000 Underlying: Class A Common Stock · 160,000 shares Expires 2036-01-29 F5 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 21:52 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 3,611 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001437749-26-002575 · rdgdoc.xml · derivative · entry 4 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 252,778 Underlying: Class A Common Stock · 3,611 shares Expires 2035-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F4 · derivative.exercise_date: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 21:52 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 811 | $14.48 | $11,747.17 |
DisclosureSEC source: 0001437749-26-002575 · rdgdoc.xml · nonDerivative · entry 3 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 21:52 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 2,800 | $14.09 | $39,441.08 |
DisclosureSEC source: 0001437749-26-002575 · rdgdoc.xml · nonDerivative · entry 2 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 811 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $14.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 21:52 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 3,611 | $4.50 | $16,249.50 |
DisclosureSEC source: 0001437749-26-002575 · rdgdoc.xml · nonDerivative · entry 1 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 21:12 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionStock Option (right to buy) · Derivative | 3,611 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001437749-25-038938 · rdgdoc.xml · derivative · entry 3 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,389 Underlying: Class A Common Stock · 3,611 shares Expires 2035-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F3 · derivative.exercise_date: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 21:12 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | SaleClass A Common Stock | 3,611 | $12.06 | $43,558.41 |
DisclosureSEC source: 0001437749-25-038938 · rdgdoc.xml · nonDerivative · entry 2 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 21:12 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | Exercise / conversionClass A Common Stock | 3,611 | $4.50 | $16,249.50 |
DisclosureSEC source: 0001437749-25-038938 · rdgdoc.xml · nonDerivative · entry 1 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Read SEC document |
| April 28, 2025 Filed Apr 28, 2025 20:21 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001437749-25-013340 · rdgdoc.xml · derivative · entry 2 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Class A Common Stock · 26,000 shares Expires 2035-04-27 F2 · derivative.exercise_date: Options granted outside of the Plan, pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). This grant is subject to a performance-based vesting condition to be satisfied upon the achievement of a particular clinical milestone, based on such performance condition being satisfied within two years of the grant date and subject to the Reporting Person's continuous service. Read SEC document |
| April 28, 2025 Filed Apr 28, 2025 20:21 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 260,000 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001437749-25-013340 · rdgdoc.xml · derivative · entry 1 Watkins Tim · CIK 0002065965 · CMO & Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Class A Common Stock · 260,000 shares Expires 2035-04-27 F1 · derivative.exercise_date: Options granted outside of the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). One-half of the option shares vest on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.